AR and cancer: This study provides further evidence of the role of the androgen receptor (AR) and its truncated splice variants (SVs) in HCC and offers valine–niclosamide as a candidate therapeutic that addresses not only AR signaling in HCC but also other known pro-cancer signaling pathways.